Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility
about
Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicinePublic preferences for the return of research results in genetic research: a conjoint analysisAlzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics.The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposesEmerging issues in public health genomics.Public perceptions of presymptomatic testing for Alzheimer diseaseDirect-to-consumer genomics on the scales of autonomy.Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review.Timing and context: important considerations in the return of genetic results to research participants.Was it worth it? Patients' perspectives on the perceived value of genomic-based individualized medicine.Patients' perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project.The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic researchGenetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.Research participant interest in primary, secondary, and incidental genomic findings.Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease.Personal utility in genomic testing: is there such a thing?The price of whole-genome sequencing may be decreasing, but who will be sequenced?Genesurance Counseling: Genetic Counselors' Roles and Responsibilities in Regards to Genetic Insurance and Financial Topics.Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada).Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening
P2860
Q26783472-003E7447-4AE5-46FE-9126-BFD4FFE8ED7EQ27324226-A58B0270-B5F1-45A0-872B-04752AC3CC27Q30244736-94093A20-6DE7-4920-BA9E-C184609F5097Q30317953-4A281FC0-108D-4382-B95B-A8AF85A2B1B6Q34496940-15E39406-A21D-44EC-8E48-77507BF40C81Q35206422-C31B05DA-0C97-4A3E-840B-2DA0DFEB75C0Q35351251-B2525FDB-29E8-42E1-9D96-5D1E41E18441Q36090201-9187F250-BBE8-47C5-8087-8D59D9D7EECCQ36470928-1F946B27-AE4C-4756-A6C6-BCC1F29C5740Q36698414-B6B5C39B-32EF-43A7-933F-EC79C8A28726Q36724985-456F19C1-D529-41FD-9241-19028C4636D1Q37116458-F909F907-48DE-4E6F-9FCD-2DA94C2C50C0Q37170455-4AC25350-0262-4885-8622-9FFD57EC06F6Q37358417-5C223C50-A0ED-4847-AD94-23594B4D8945Q37690501-D5CC1162-F32D-4FA7-ADD2-852DFA8A24ECQ45299444-B8032CBA-1C22-4FCA-B9D2-DEBF0F3E7158Q46829097-CE16D014-18ED-4216-9C79-35BE22BB3B73Q47369252-D87034CC-CBA7-42CD-AA52-AF4594CF4317Q52682549-C0B789CA-BAA6-4211-BE8B-543237046660Q55407214-A7BF0EBF-C02E-4A92-B05D-DC4AF6F8F018Q57071839-EFD83813-2CD3-4038-BB86-7C0C61AD08F7
P2860
Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Willingness to pay for genetic ...... a measure of personal utility
@ast
Willingness to pay for genetic ...... a measure of personal utility
@en
type
label
Willingness to pay for genetic ...... a measure of personal utility
@ast
Willingness to pay for genetic ...... a measure of personal utility
@en
prefLabel
Willingness to pay for genetic ...... a measure of personal utility
@ast
Willingness to pay for genetic ...... a measure of personal utility
@en
P2093
P2860
P356
P1476
Willingness to pay for genetic ...... a measure of personal utility
@en
P2093
Clara Chen
Ilona M Kopits
J Scott Roberts
Wendy Uhlmann
P2860
P304
P356
10.1089/GTMB.2011.0028
P577
2011-07-12T00:00:00Z